Stereotaxis, Inc. Common Stock (STXS) is a publicly traded Healthcare sector company. As of May 21, 2026, STXS trades at $1.85 with a market cap of $173.97M and a P/E ratio of -7.65. STXS moved +6.94% today. Year to date, STXS is -21.61%; over the trailing twelve months it is -11.48%. Its 52-week range spans $1.54 to $3.59. Analyst consensus is strong buy with an average price target of $4.13. Rallies surfaces STXS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Stereotaxis Secures Approval for Next-Gen System and Reports Year-Over-Year Revenue Growth: During Q1 2026, Stereotaxis announced regulatory approvals for its next-generation catheter navigation system and reported year-over-year revenue growth driven by increased US hospital deployments. Executives detailed planned FDA submissions for expanded indications and confirmed European market launch in H2 2026.
| Metric | Value |
|---|---|
| Price | $1.85 |
| Market Cap | $173.97M |
| P/E Ratio | -7.65 |
| EPS | $-0.24 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.59 |
| 52-Week Low | $1.54 |
| Volume | 150 |
| Avg Volume | 0 |
| Revenue (TTM) | $-681.00K |
| Net Income | $-21.68M |
| Gross Margin | -2467.11% |
4 analysts cover STXS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $4.13.